MGMT and glioblastoma: In that regard, bortezomib, a drug approved for the treatment of multiple myeloma, depletes MGMT levels in patient-derived unmethylated GBM cells, resulting in the re-sensitization of TMZ-resistant unmethylated GBM cells [56].